US equities
|
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MU
$934.27
▼-4.98%
MSFT
$530.14
▼-0.16%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MU
$934.27
▼-4.98%
MSFT
$530.14
▼-0.16%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Tryp Therapeutics Inc
(OP:
TRYPF
)
N/A
UNCHANGED
Last Price
Updated: 3:17 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tryp Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
May 01, 2024
Via
ACCESSWIRE
Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
↗
April 25, 2024
Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore merger details now!
Via
Benzinga
BioMedNewsBreaks — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited
April 24, 2024
Via
Investor Brand Network
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
April 24, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting
March 13, 2024
Via
Investor Brand Network
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
March 12, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders
February 09, 2024
Via
Investor Brand Network
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
February 08, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for ‘Pivotal’ Two-Cent Waiver
January 26, 2024
Via
Investor Brand Network
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
January 26, 2024
Via
ACCESSWIRE
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
↗
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
↗
January 08, 2024
Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones.
Via
Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches ‘Significant Milestone’
January 08, 2024
Via
Investor Brand Network
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
January 08, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Dosing of First Patient in Phase 2a TRP-8802 Clinical Trial
January 04, 2024
Via
Investor Brand Network
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
January 04, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Inks Definitive Agreement with Exopharm Limited
December 11, 2023
Via
Investor Brand Network
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
December 11, 2023
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement
November 20, 2023
Via
Investor Brand Network
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
November 20, 2023
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement
November 02, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement
October 12, 2023
Via
Investor Brand Network
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
October 11, 2023
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Life Sciences Exec as New CEO
August 03, 2023
Via
Investor Brand Network
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
August 03, 2023
Via
ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Reports on the Passing of Director David Tousley
August 02, 2023
Via
Investor Brand Network
With Great Sadness Tryp Announces the Passing of David Tousley, Director
August 02, 2023
Via
ACCESSWIRE
Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy's Garden And More
↗
July 19, 2023
GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote
Via
Benzinga
Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital
↗
July 13, 2023
Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital...
Via
Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Proceed with Phase 2A Clinical Trial in Patients with IBS
July 13, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
Next >
